1510440598 IUSCC-0551; A Phase I/Ib Open Label Dose Finding Study to Evaluate Safety Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma



Study Overview

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.


Study Description

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.

Research Study Identifier: TX5640
ClinicalTrials.gov Identifier: NCT1510440598


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.